Julie Martin
Prisma Health(US)University of South Carolina(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Galectins and Cancer Biology, Lung Cancer Treatments and Mutations, RNA modifications and cancer, Glycosylation and Glycoproteins Research
Most-Cited Works
- → Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors(2013)105 cited
- → Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer(2013)100 cited
- → Centering the Marginalized Student’s Voice Through Autoethnography: Implications for Engineering Education Research(2020)49 cited
- → Disabled-2 downregulation promotes epithelial-to-mesenchymal transition(2010)47 cited
- → An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors(2009)42 cited
- → A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy(2011)40 cited